10 completed. 10 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Completed 10 |
| Phase 3 | 1 | Completed 1 |
Follow Cold Urticaria: new trials by email Literature Review of Cold Urticaria trials Research Report on Cold Urticaria
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate VTX2735 in Patients With Cryopyrin-associated Periodic Syndrome VTX2735 - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zomagen Biosciences Ltd. | 7 | 2023-03-18 | 2025-03-10 |
| A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZYIL1 in Subjects With Cryopyrin Associated Periodic Syndromes (CAPS) ZYIL1 capsule - Cryopyrin Associated Periodic Syndrome | Phase 2 | Completed | Zydus Lifesciences Limited | 3 | 2022-06-01 | 2022-07-11 |
| Study of Safety, Tolerability and Efficacy of DFV890 in Participants With Familial Cold Auto-inflammatory Syndrome (FCAS) DFV890 - Familial Cold Autoinflammatory Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 4 | 2021-09-20 | 2024-10-09 |
| Cold Contact Urticaria Treatment With Rilonacept Rilonacept, Placebo - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 20 | 2015-01-01 | 2018-07-17 |
| Study to Assess Efficacy, Safety and Mechanism of Rupatadine in Cold Urticaria Rupatadine - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 24 | 2012-06-01 | 2014-10-15 |
| Cold Urticaria Treatment With Xolair Omalizumab, Placebo - Cold Contact Urticaria | Phase 2 | Completed | Charite University, Berlin, Germany | 31 | 2012-04-01 | 2017-04-07 |
| Bilastine Updosing - Characterization of Underlying Mechanisms Bilastine - Cold Contact Urticaria | Phase 2 / Phase 3 | Completed | Charite University, Berlin, Germany | 20 | 2010-09-01 | 2012-05-31 |
| Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS) rilonacept - Muckle-Wells Syndrome, Schnitzler Syndrome | Phase 2 | Completed | Charite University, Berlin, Germany | 10 | 2009-01-01 | 2012-05-31 |
| Safety, Efficacy, Pharmacokinetics, Pharmacodynamics of ACZ885 in Patients With NALP3 Mutations and Clinical Symptoms canakinumab - NALP3 Mutation | Phase 2 | Completed | Novartis Pharmaceuticals | 34 | 2005-01-01 | 2009-02-17 |
| Interleukin-1 Trap to Treat Autoinflammatory Diseases IL-1 Trap - Inflammation, Familial Mediterranean Fever | Phase 2 | Completed | National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | 11 | 2004-10-01 | 2014-03-04 |
Cryopyrin-Associated Periodic Syndromes (6) · Familial Mediterranean Fever (1) · Fever (1) · Inflammation (1) · Schnitzler Syndrome (1) · Still's Disease, Adult-Onset (1) · Urticaria (1)
Hypersensitivity (10) · Hypersensitivity, Immediate (10) · Immune System Diseases (10) · Skin Diseases (10) · Skin Diseases, Vascular (10) · Skin and Connective Tissue Diseases (10) · Urticaria (9) · Chronic Disease (6) · Chronic Inducible Urticaria (6) · Chronic Urticaria (6) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Disease Attributes (6) · Genetic Diseases, Inborn (6) · Hereditary Autoinflammatory Diseases (6)
rilonacept (3) · Omalizumab (1) · ZYIL1 (1) · bilastine (1) · canakinumab (1) · rupatadine (1)
Charite University, Berlin, Germany (5) · Novartis Pharmaceuticals (2) · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) (1) · Zomagen Biosciences Ltd. (1) · Zydus Lifesciences Limited (1)
Germany (7) · United States (3) · France (2) · Australia (1) · India (1) · Spain (1) · United Kingdom (1)
Karoline Krause, MD (2) · Marcus Maurer, MD (2) · Dr Deven Parmar, MD (1) · Henrik Sonnergren, MD, PhD (1) · Martin Metz, MD (1)
PMID 18668591, PMID 21356079, PMID 22583335, PMID 28389393, PMID 36973954